Prognostic Value of Intratumor Metabolic Heterogeneity Parameters on ¹⁸F-FDG PET/CT for Patients with Colorectal Cancer

Table 3

Univariate and multivariate Cox regression analyses (radical treatment).

Variables	PFS						OS
	Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis
	HR	95% CI	value	HR	95% CI	value	HR	95% CI	value	HR	95% CI	value
Age	0.99	0.96–1.01	0.252				0.98	0.93–1.02	0.210
Gender
Male	1.00						1.00
Female	0.76	0.36–1.59	0.458				0.25	0.03–2.06	0.199
Tumor location
Right colon	1.00						1.00
Left colon	1.51	0.62–3.68	0.346				1.28	0.25–6.42	0.766
Rectum	1.26	0.54–3.00	0.590				0.62	0.10–3.71	0.599
Pathological types
Adenocarcinoma	1.00						1.00
MAC/SRC	2.05	0.95–4.42	0.068				1.63	0.33–8.11	0.551
Differentiation
LD	1.00						1.00
MD/HD	0.77	0.37–1.63	0.498				0.97	0.20–4.81	0.971
Tumor diameter	1.11	0.92–1.35	0.262				1.27	0.85–1.89	0.238
T Stage
T1-2	1.00						1.00
T3-4	1.26	0.57–2.81	0.565				0.37	0.09–1.49	0.163
Regional lymph nodes
N–	1.00						1.00
N+	2.54	1.26–5.12	0.009	0.16	0.04–0.57	0.005	1.56	0.39–6.24	0.533
Nerve invasion
Negative	1.00						1.00
Positive	2.24	0.89–5.65	0.087				1.58	0.18–13.62	0.679
Tumor thrombus
Negative	1.00						1.00
Positive	3.85	1.90–7.80	<0.001	1.48	0.65–3.36	0.351	3.19	0.76–13.43	0.115
Stage, AJCC
I-II	1.00						1.00
III	3.67	1.74–7.75	0.001	20.65	4.81–88.62	<0.001	1.37	0.34–5.50	0.654
CEA (ng/ml)
Normal (≤5.00)	1.00						1.00
Increased (>5.00)	1.94	1.00–3.90	0.061				4.50	0.90–22.45	0.067
CA19-9 (U/ml)
Normal (≤37.00)	1.00						1.00
Increased (>37.00)	1.09	0.49–2.41	0.839				1.24	0.25–6.18	0.790
SUVmax	0.97	0.92–1.02	0.256				1.00	0.91–1.11	0.938
SUVmean	0.93	0.84–1.03	0.169				1.01	0.84–1.21	0.926
SUVpeak	0.97	0.90–1.04	0.396				1.03	0.90–1.18	0.687
MTV (ml)	1.02	1.01–1.04	0.012	0.98	0.96–1.01	0.279	1.03	1.00–1.06	0.016	0.96	0.92–1.01	0.122
TLG (g)	1.00	0.99–1.00	0.391				1.00	1.00–1.00	0.074
HI-1
≤0.23	1.00						1.00
>0.23	0.52	0.25–1.11	0.089				0.42	0.08–2.07	0.284
HI-2	1.07	1.04–1.10	<0.001	1.10	1.04–1.17	0.001	1.10	1.05–1.15	<0.001	1.16	1.07–1.26	<0.001

PFS, progression-free survival; OS, overall survival; MAC, mucinous adenocarcinoma; SRC, signet ring cell carcinoma; LD, low-differentiation; MD, middifferentiation; HD, High-differentiation; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; SUV, standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; HI, heterogeneity index. Bold values, P < 0.05.